1235032-75-3

1235032-75-3 structure

Name: Bcl-xL antagonist 2
Chemical Name: Bcl-xL antagonist 2
CAS Number: 1235032-75-3
Molecular Formula: C₂₁H₁₆N₄O₃S₂
Molecular Weight: 436.51
Catalog: Signaling Pathways Apoptosis Bcl-2 Family
Create Date: 2022-03-03 20:43:22
Modify Date: 2025-08-26 21:24:00
Bcl-xL antagonist 2 is a potent, selective, and orally active antagonist of BCL-XL with an IC50 and Ki of 0.091 μM and 65 nM, respectively. Bcl-xL antagonist 2 promotes the apoptosis of cancer cells. Bcl-xL antagonist 2 has the potential for the research of the chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL)[1][2].

Name	Bcl-xL antagonist 2

Description	Bcl-xL antagonist 2 is a potent, selective, and orally active antagonist of BCL-XL with an IC50 and Ki of 0.091 μM and 65 nM, respectively. Bcl-xL antagonist 2 promotes the apoptosis of cancer cells. Bcl-xL antagonist 2 has the potential for the research of the chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL)[1][2].
Related Catalog	Signaling Pathways >> Apoptosis >> Bcl-2 Family Research Areas >> Cancer
Target	0.091 μM (BCL-XL)[1]
In Vivo	Assessment of Pharmacokinetics (PK) profile of Bcl-xL antagonist 2 (compound 14) in rat[1]. iv (1 mg/kg) po (5 mg/kg) CLp (mL/min/kg) Vss (L/kg) t 1/2 (h) F % 0.47 0.16 6.0 16
References	[1]. Koehler MF, et al. Structure-Guided Rescaffolding of Selective Antagonists of BCL-XL. ACS Med Chem Lett. 2014;5(6):662-667. [2]. Wang L, et al. Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-XL Inhibitor. ACS Med Chem Lett. 2020;11(10):1829-1836.

Molecular Formula	C₂₁H₁₆N₄O₃S₂
Molecular Weight	436.51